

Metastatic NSCLC

Abstract 9006

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. <https://bit.ly/3vpQjyw>

Abstract 9007

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). <https://bit.ly/3i2mxvX>

Abstract 9003

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreak 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

<https://bit.ly/3fiXCSa>

Abstract 9001

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis <https://bit.ly/3ur0eCk>

Abstract 9000

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC):

Two-year update from CheckMate 9LA. <https://bit.ly/3vt8D9I>

Abstract 9008

Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. <https://bit.ly/2Tq5oC9>

Abstract 9013

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm). <https://bit.ly/3fpREzO>

Abstract 9002

Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. <https://bit.ly/3fOM1dI>

Abstract 9009

OS w/ctDNA guiding mgmt in advanced NSCLC

Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer. <https://bit.ly/2SwA7Nc>

Abstract 9007

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). <https://bit.ly/3vqZqyS>

Local NSCLC/ SCLC

Abstract 8500

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). <https://bit.ly/2SAmjRG>

Abstract 8503

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). <https://bit.ly/3wCsLGJ>

Abstract 8501

Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial. <https://bit.ly/2SxViP7>

Abstract 8502

CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer. <https://bit.ly/3bWTZjm>

Abstract 8510

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). <https://bit.ly/3hXK1C3>

Abstract 8508

Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers <https://bit.ly/3uk7zUs>

Abstract 8517:

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC <https://bit.ly/3wB3rkn>

Abstract 8534

Sequential monitoring of PD-L1 on circulating stromal cells in blood predicts PFS in NSCLC patients undergoing immunotherapy after definitive chemoradiation. <https://bit.ly/3fNAV8x>

Abstract 8507

A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma <https://bit.ly/34onSVz>